Active substance
Poliomyelitis vaccine
- SFDA 5
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| IMOVAX POLIO SUSPENSION FOR IM OR SC Injection* | Solution · Intramuscular use | 1 Vial | SAR 42.00 | Biological · Prescription | SANOFI PASTEUR | Withdrawn by MAH · Not Marketed | |
| OPVERO | Oral drops, suspension · Oral use | 10 Vial | SAR 175.50 | Biological · Prescription | SANOFI PASTEUR | Withdrawn by MAH · Not Marketed | |
| OPVERO | Oral drops, suspension · Oral use | 10 Vial | SAR 87.75 | Biological · Prescription | SANOFI PASTEUR | Withdrawn by MAH · Not Marketed | |
| ORAL BIVALENT TYPES 1 and 3 POLIOMYELITIS VACCINE | Oral suspension · Oral use | 10 Applicator | SAR 50.00 | Biological · Prescription | SANOFI PASTEUR | Withdrawn by MAH · Not Marketed | |
| POLIOSABIN ORAL VACCINE | Oral drops, suspension · Oral use | 1 Vial | SAR 15.15 | Biological · Prescription | GLAXOSMITHKLINE (GSK) | Withdrawn by MAH · Not Marketed |
WHO WHO Model List of Essential Medicines (2025)
- 19.3. Immunologicals > Vaccines · core
Need for immunization against poliomyelitis
All vaccines should comply with the WHO requirements for biological substances.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.